EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtOpen Access

Mucormycosis in COVID-19: A systematic review of literature

Shivaraj Nagalli, Nidhi Shankar Kikkeri

Infezioni in Medicina · 10.12.2021 · 29 (4)

DOI: 10.53854/liim-2904-2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Infezioni in Medicina, online erschienen am 10.12.2021. Verfasst von Shivaraj Nagalli und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Brookwood Baptist Health, Alabaster, USA. Die Arbeit wurde bisher 16-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Coronavirus disease 2019 (COVID-19) is an acute viral illness caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Opportunistic infections such as mucormycosis have been reported among COVID-19 patients particularly in South Asian countries during the second wave of this pandemic. It is necessary to re-evaluate any changes in traditional risk factors associated with mucormycosis such as diabetes mellitus, organ transplant, etc in the precedent of ongoing COVID-19 pandemic. We conducted a systematic review using electronic databases. A total of 115 COVID-19 patients who were diagnosed with mucormycosis were included in this study. Diabetes mellitus was the most common co-morbidity with 77.1%, followed by hypertension (29.5%) and renal disease (14.3%). 55.2% of the patients had received dexamethasone for COVID-19 infection. Ten patients (11.5%) had received tocilizumab. Sinuses were the most common site of mucormycosis among COVID-19 patients at 79.4% with maxillary sinus (47.4%) being most commonly infected. Orbits were the second most prevalent site at 56.7% and lungs were infected with mucor at 11.3%. The mean duration between the diagnosis of COVID-19 infection and mucormycosis was 16.15 days (range 2-90 days). Cavernous sinus was either infiltrated or encased in 14 patients (14.4%). Cerebral involvement was seen in terms of abscess, infarcts, or edema in 12 patients (12.4%). Only 76 patients had data on the outcomes, out of which 37 (48.7%) patients had died. Diabetes mellitus is still the most common co-morbidity similar to non-COVID-19 patients. More than 90% of the patients with COVID-19 infection had received steroids. Complications such as cavernous sinus thrombosis, cerebral infarcts, abscesses were common. Indiscriminate use of steroids in patients needs to be avoided and focus needs to be put on tight blood sugar control in diabetic patients. Studies are needed to confirm the role of the SARS-CoV-2 virus in causing immune dysfunction and mucormycosis.

Schlagwörter

Stichwörter der Autor:innen

COVID-19Mucormycosisdiabetes mellitussinussteroids

Autor:innen und Institutionen

  • Department of Internal Medicine, Brookwood Baptist Health, Alabaster, USA.
  • Department of Neurology, University of Alabama, Birmingham, USA.

Zitieren

APA

Nagalli, S., & Kikkeri, N. S. (2021). Mucormycosis in COVID-19: A systematic review of literature. Infezioni in Medicina, 29(4). https://doi.org/10.53854/liim-2904-2

Vancouver

Nagalli S, Kikkeri NS. Mucormycosis in COVID-19: A systematic review of literature. Infezioni in Medicina. 2021;29(4). doi:10.53854/liim-2904-2

BibTeX
@article{Nagalli2021,
  author = {Nagalli, Shivaraj and Kikkeri, Nidhi Shankar},
  title = {Mucormycosis in COVID-19: A systematic review of literature},
  journal = {Infezioni in Medicina},
  year = {2021},
  volume = {29},
  number = {4},
  doi = {10.53854/liim-2904-2}
}
Kostenlos starten →